FDDNP Protocol for Visualizing Brain Proteinopathies to Assist in the Diagnosis of Persons With Suspected CTE and AD

FDDNP Protocol for Visualizing Brain Proteinopathies to Assist in the Diagnosis of Persons With Suspected CTE and AD

Publication date: Mar 17, 2020

The primary objective of this study is to demonstrate the safety and efficacy of positron emission tomography (PET) imaging with a radioactive compound called [F-18]FDDNP in subjects with suspected Alzheimer’s disease or suspected chronic traumatic encephalopathy (CTE) to predict clinical decline after one and two years.

Concepts Keywords
Albumin Magnetic resonance imaging
Alcohol Abuse Clinical protocols
Allergic Reactions Severe anemia
Alzheimer Mental disorder
Anemia Neurologic disorder
Anxiety Mild cognitive impairment
Aspirin Major depressive disorder
Ataxia Neurologic physical illness
Blood Dementia
Bradykinesia History head trauma
California Anxiety depression
Cancer Clinical protocols
Cardiac Failure Cognitive disorders
Chronic Traumatic Encephalopathy Psychiatric diagnosis
Cocaine Psychiatry
Cognitive Medicine
Cognitive Dysfunction Medical specialties
Comorbid RTT
Concussion Learning disabilities
Contraindicated Neurotrauma
Delirium Mild cognitive impairment
Dementia Chronic traumatic encephalopathy
Depression Alzheimer’s disease
Diabetes Dementia
Diastolic Imaging clinical protocols
Diclofenac Magnetic resonance imaging
Dysarthria Tomography
Dysphagia MRI
Emotional Dysregulation
Encephalopathy
Executive Functioning
Gait
Head Trauma
Heroin
Hypertension
Ibuprofen
Impulse Control
Informed Consent
Insidious
Interpersonal Relationships
Jak
Los Angeles
Magnetic Resonance Imaging
Major Depressive Disorder
Mania
Marijuana
Medicine
Memory
Menopausal
Menses
Mental Disorder
Mild Cognitive Impairment
MRI
MRI Scan
Multiple Sclerosis
Naproxen
Neurologic Disorder
Neurological
Neuropsychiatric
Neuropsychological
Neuropsychological Testing
Neuropsychological Tests
Nursing
Observer
Paranoid Ideation
PET Imaging
PET Scan
Positron Emission Tomography
Pregnancy Test
Prescription Drug
Progressive
Psychiatric Disorder
Psychosis
Radioactive
Schizophrenia
Serum
Standard Deviation
Stroke
Substance Abuse
Suicidality
Symptom
Syndrome
Systolic
Trauma
Tremor
UCLA
Visuospatial

Semantics

Type Source Name
disease MESH Diagnosis
disease MESH chronic traumatic encephalopathy
disease MESH mild cognitive impairment
disease MESH dementia
drug DRUGBANK Isoxaflutole
disease MESH encephalopathy
disease MESH syndrome
disease MESH neurologic disorder
disease MESH depression
disease MESH anxiety
disease MESH violence
disease MESH apathy
disease MESH substance abuse
disease MESH bradykinesia
disease MESH tremor
disease MESH gait
disease MESH dysarthria
disease MESH dysphagia
disease MESH ataxia
disease MESH delirium
drug DRUGBANK Tropicamide
disease MESH mental disorder
disease MESH major depressive disorder
disease MESH schizophrenia
disease MESH visual
disease MESH TICS
disease MESH psychosis
disease MESH stroke
disease MESH multiple sclerosis
disease MESH cancer
disease MESH mania
disease MESH alcohol abuse
drug DRUGBANK Medical Cannabis
drug DRUGBANK Cocaine
drug DRUGBANK Diamorphine
disease MESH allergic reactions
disease MESH anemia
disease MESH cardiac failure
disease MESH cardiac disease
disease MESH hypertension
drug DRUGBANK Ibuprofen
drug DRUGBANK Naproxen
drug DRUGBANK Diclofenac
drug DRUGBANK Acetylsalicylic acid
disease MESH Alzheimer Disease
pathway KEGG Alzheimer disease

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *